SLC16A1 and breast cancer: Silencing MCT1 can inhibit the NF-κB signaling pathway and the migration and metastasis of breast cancer cells while restoring MCT1 expression restore the NF-κB activation-dependent migration of cancer cells (Vegran et al., 2011).